MetaCap

IRulya Therapeutics (IRLA) vs Tectonic Therapeutic (TECX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

IRulya Therapeutics is the larger company by market cap ($432.4 million vs $405.3 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

IRLA+17.16%TECX-40.62%
+22%-13%-49%
Aug 14, 20261 yearNov 20, 2026
IRLA+17.16%TECX-40.62%
+20%-13%-46%
Aug 10, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

IRLA versus TECX key metrics
MetricIRLATECX
Share price$39.88$20.73
Market cap$432.36M$405.26M
1-day change-0.15%-1.47%
YTD return—-0.62%
1-year return—+8.08%
5-year return—-57.66%
EPS (TTM)$-162.79$-4.63
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-83.98M$-74.15M
52-week high$910.00$39.53
52-week low$15.10$16.77
Distance from 52-week high-95.62%-47.56%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+90.90%+242.50%
Average volume63.03K212.16K
Shares outstanding10.84M19.55M
Employees3860
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About IRulya Therapeutics

IRLA stock →

IRulya Therapeutics Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidate comprises eDSP, which is in Phase 3 for the treatment of rare pediatric neurodegenerative diseases, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in the ATM gene.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 38 employees

About Tectonic Therapeutic

TECX stock →

Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 60 employees

IRLA vs TECX FAQ

Which is bigger, IRulya Therapeutics or Tectonic Therapeutic?

IRulya Therapeutics (IRLA) is larger, with a market capitalization of $432.36M compared with $405.26M for Tectonic Therapeutic (TECX).

Are IRulya Therapeutics and Tectonic Therapeutic in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons